PSTV Stock Risk & Deep Value Analysis
Plus Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PSTV Stock
We analyzed Plus Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PSTV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PSTV Risk Analysis & Red Flags
What Could Go Wrong
The primary risk is clinical trial failure for REYOBIQ™. A negative or inconclusive outcome in ongoing or future trials would devastate the valuation, as the entire 10x thesis is predicated on the success and commercialization of this lead asset. The company's future financing capabilities would also be severely hampered.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Increased net loss in 2025 (though offset by improved cash position from financing)
- ⚠
Reverse stock split indicating previous stock price fragility and delisting risk
- ⚠
Continued heavy cash burn requiring future dilutive financing
- ⚠
Binary clinical outcomes represent significant event risk
Upcoming Risk Events
- 📅
Negative or inconclusive clinical trial results for REYOBIQ™
- 📅
Delayed patient enrollment or trial progression
- 📅
Need for further dilutive financing if cash burn accelerates
- 📅
Increased competition in the radiopharmaceutical oncology space
When to Reconsider
- 🚪
Negative or non-efficacious clinical trial results for REYOBIQ™
- 🚪
Cash balance dropping below $5 million without a clear financing plan
- 🚪
Failure to achieve subsequent regulatory milestones after Orphan Drug Designation
- 🚪
Issuance of a delisting notice from Nasdaq due to non-compliance
Unlock PSTV Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Plus Therapeutics Inc (PSTV) Do?
Market Cap
$37.26M
Sector
Healthcare
Industry
Biotechnology
Employees
21
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Visit Plus Therapeutics Inc WebsiteInvestment Thesis
Plus Therapeutics presents a compelling high-risk, high-reward investment in the targeted radiopharmaceutical space, focusing on high-unmet-need oncology. Recent significant improvements in financial health (increased cash, positive equity) and a critical regulatory milestone (Orphan Drug Designation for REYOBIQ™) de-risk the immediate outlook. The 10x potential is driven by successful clinical development of REYOBIQ™ for recurrent glioblastoma and other indications, which could lead to substantial market re-rating.
Is PSTV Stock Undervalued?
Unlock the full AI analysis for PSTV
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PSTV Price Targets & Strategy
12-Month Target
$15.00
Bull Case
$50.00
Bear Case
$1.00
Valuation Basis
Implied valuation of ~$0.1B market cap (2x current) based on de-risked balance sheet and Orphan Drug Designation, anticipating further pipeline progress within 12 months. (Market Cap / Shares Outstanding)
Entry Strategy
Dollar-cost average between $5.00-$7.00, focusing on dips after current price volatility from reverse split settles.
Exit Strategy
Take partial profits at $15.00 (short-term de-risking target) and $30.00 (mid-term clinical success anticipation). Implement a stop-loss order below $3.00 if clinical or financial outlook deteriorates.
Portfolio Allocation
3% for aggressive risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is PSTV Financially Healthy?
Profitability
Gross Margin
74.77%
Operating Margin
-293.46%
Net Margin
-429.43%
Return on Equity
-123.76%
Revenue Growth
-10.49%
EPS
$-1.25
Balance Sheet
Current Ratio
1.23
Quick Ratio
1.12
Debt/Equity
0.19
Cash & Equivalents
$13.10M
Other
Beta (Volatility)
1.86
Does PSTV Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is currently strengthening with regulatory designations and ongoing clinical development, but its long-term durability is contingent on successful clinical trials, regulatory approvals, and sustained intellectual property protection against emerging competitors in the radiopharmaceutical space. Clinical success will solidify the moat.
Moat Erosion Risks
- •Clinical trial failure negates IP value and regulatory advantages.
- •Emergence of superior or more cost-effective competing therapies.
- •Intellectual property challenges or patent expirations.
PSTV Competitive Moat Analysis
Sign up to see competitive advantages
PSTV Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral. Limited broad retail discussion, sentiment is likely tied to specific clinical news.
Institutional Sentiment
Neutral. No analyst coverage provided. Recent inducement awards to new employees indicate growth initiatives, but no material institutional buying/selling trends are available.
Insider Activity (Form 4)
Andrew Sims (CFO) exercised 67,452 RSUs on April 1, 2026, which is equity compensation realization. Randy H. Goodman (VP) was granted 4,500 stock options and 4,500 RSUs on April 13, 2026 as an inducement award. Inducement awards were also granted to two other new employees (300,000 stock options and 300,000 RSUs) on March 26, 2026. No material discretionary insider buying or selling detected.
Options Flow
Normal options activity.
Earnings Intelligence
Next Earnings
Estimated August 2026 for Q1 2026 (based on historical patterns)
Surprise Probability
Low
Historical Earnings Pattern
Stock price reaction is highly sensitive to news regarding clinical trial progress and regulatory milestones, rather than purely financial results for a clinical-stage company.
Key Metrics to Watch
Competitive Position
Top Competitor
TELIX
Market Share Trend
Not applicable; pre-commercialization. Aiming to establish market share in niche oncology markets.
Valuation vs Peers
Difficult to compare directly due to early stage. PSTV's market cap ($0.04B) is significantly smaller than more advanced radiopharma peers (e.g., Telix Pharmaceuticals with ~$1.7B market cap), suggesting substantial upside if its lead asset progresses.
Competitive Advantages
- •FDA Orphan Drug Designation for REYOBIQ™ (7 years market exclusivity post-approval)
- •NIH partnership provides validation and funding
- •Proprietary targeted radiotherapeutic platform for difficult-to-treat cancers
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PSTV Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings report (expected Q3 2026, Aug. based on historical pattern)
- •Updates on RNL (REYOBIQ™) clinical trial enrollment and progression
- •Strategic partnerships leveraging Orphan Drug Designation
Medium-Term (6-18 months)
- •Interim data readouts from RNL clinical trials (e.g., Phase 2 rGBM)
- •Potential expansion of REYOBIQ™ into additional oncology indications
- •Further regulatory milestones or fast track designations
Long-Term (18+ months)
- •Successful Phase 3 trial completion and FDA approval of REYOBIQ™
- •Establishment of REYOBIQ™ as a standard of care for rGBM or other indications
- •Expansion of radiopharmaceutical pipeline
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PSTV?
- ✓
Positive clinical data readouts for REYOBIQ™
- ✓
Sustained cash balance above $10M, indicating responsible cash management
- ✓
Updates on strategic partnerships or licensing agreements
Bull Case Analysis
See what could go right with Premium
Competing with PSTV
See how Plus Therapeutics Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Plus Therapeutics Inc PSTV | $37.3M | 4.4 | — | — | -429.4% | -10.5% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Plus Therapeutics Inc Makes Money
Plus Therapeutics is a clinical-stage pharmaceutical company dedicated to developing innovative targeted radiotherapeutics for difficult-to-treat cancers, particularly those in the central nervous system. Their lead product, REYOBIQ™ (rhenium-186 obisbemeda), is designed to deliver radiation directly to tumor cells, aiming for improved efficacy and reduced side effects compared to conventional treatments. The company generates limited revenue from grants but primarily funds its extensive research and development through dilutive equity financing. The long-term business model relies on successfully navigating clinical trials and regulatory approval processes to eventually commercialize its proprietary drug candidates, either independently or through partnerships, to generate significant sales or licensing revenue.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Plus Therapeutics Inc (PSTV)?
As of April 16, 2026, Plus Therapeutics Inc has a DVR Score of 4.4 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Plus Therapeutics Inc?
Plus Therapeutics Inc's market capitalization is approximately $37.3M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Plus Therapeutics Inc use?
PSTV is the ticker symbol for Plus Therapeutics Inc. The company trades on the NCM.
What is the risk level for PSTV stock?
Our analysis rates Plus Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Plus Therapeutics Inc's revenue growing?
Plus Therapeutics Inc has reported revenue growth of -10.5%. Revenue has been declining, which warrants closer examination.
Is PSTV stock profitable?
Plus Therapeutics Inc has a profit margin of -429.4%. The company is currently unprofitable.
How often is the PSTV DVR analysis updated?
Our AI-powered analysis of Plus Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 16, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PSTV (Plus Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.